Peptic Ulcers Drug Development- Pipeline Analysis Report

Peptic Ulcers Drug Development- Pipeline Analysis Report

  • May 2018 •
  • Report ID: 5390304 •
  • Format: PDF
Atleast 10% of US population suffers from peptic ulcers in a lifetime. The serious condition observes ulcers in stomach and beginning of small intestine or lining of the esophagus. The market value is estimated to be around half billion USD in 2020. In particular, aged popultion and female gender are more susceptible to the disease.

Over 20 companies and universities are focusing on developing treatment options for Peptic Ulcers.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Peptic Ulcers pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Peptic Ulcers pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Peptic Ulcers pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.